Sugi Predict

Sugi Predict / Targets / GSAP

GSAP

Gamma-secretase-activating protein · A4D1B5 · GSAP on Sugi Atlas →

2,072 patent compounds predicted against GSAP, 1,650 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL453583 SCHEMBL453583 1.00 1/20
SCHEMBL453584 SCHEMBL453584 1.00 1/20
Nirogacestat Nirogacestat (SCHEMBL1796299) 1.00 1/20
SCHEMBL2679837 SCHEMBL2679837 1.00 1/20
SCHEMBL2685774 SCHEMBL2685774 1.00 1/20
SCHEMBL4413288 SCHEMBL4413288 0.92 1/20
SCHEMBL1794892 SCHEMBL1794892 0.90 1/20
SCHEMBL4413442 SCHEMBL4413442 0.89 1/20
SCHEMBL4985301 SCHEMBL4985301 0.88 1/20
SCHEMBL4552344 SCHEMBL4552344 0.85 1/20
SCHEMBL4413345 SCHEMBL4413345 0.84 1/20
SCHEMBL4417214 SCHEMBL4417214 0.84 1/20
SCHEMBL1797384 SCHEMBL1797384 0.83 1/20
SCHEMBL4424704 SCHEMBL4424704 0.83 1/20
SCHEMBL4421095 SCHEMBL4421095 0.82 1/20
SCHEMBL4418929 SCHEMBL4418929 0.82 1/20
SCHEMBL1799614 SCHEMBL1799614 0.82 1/20
SCHEMBL2980207 SCHEMBL2980207 0.81 1/20
SCHEMBL4989550 SCHEMBL4989550 0.81 1/20
SCHEMBL1797064 SCHEMBL1797064 0.81 1/20

Clinical trials — most relevant to GSAP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Lithium As a Treatment to Prevent Impairment of Cognition in Elders PHASE4COMPLETED
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET) PHASE2COMPLETED
Development of NIC5-15 in the Treatment of Alzheimer's Disease PHASE2COMPLETED
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease PHASE2COMPLETED
Sirtuin-NAD Activator in Alzheimer's Disease PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Nirogacestat in Patients With Kaposi Sarcoma PHASE2NOT_YET_RECRUITING
Dose Escalation of Desmoteplase in Acute Ischemic Stroke (DEDAS) PHASE1/PHASE2COMPLETED
MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB PHASE2COMPLETED
Pioglitazone in Alzheimer Disease PHASE2COMPLETED
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease PHASE2ACTIVE_NOT_RECRUITING
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome PHASE1/PHASE2COMPLETED
Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose) PHASE1COMPLETED
Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants PHASE1WITHDRAWN
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
Exploratory and Safety Study of [F-18]W372 EARLY_PHASE1COMPLETED
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid nanCOMPLETED
Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia nanUNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Dominantly Inherited Alzheimer Network (DIAN) nanRECRUITING
Central and Systemic Inflammation in Alzheimer's Disease nanCOMPLETED
Evaluate the Safety and Feasibility of tACS With the Miamind Neurostimulator in Healthy Participants nanCOMPLETED
Perioperative Research Into Memory, Genomics in the Intensive Therapy Unit: Alzheimer's nanUNKNOWN
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease nanENROLLING_BY_INVITATION
Exercise and the Receptor for Advanced Glycation End Products (RAGE) nanCOMPLETED
Bace1as Role in Heart Failure (BACE1AS-HF) nanCOMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING
Clearance Mechanisms in Atypical Neurodegenerative Diseases nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GSAP binder may also engage these)

ProteinNameSimilarity
Q9Z2U2 — 0.999 Q9Z2U2 →
O88480 — 0.998 O88480 →
Q8BJW5 — 0.998 Q8BJW5 →
Q5ZLS8 — 0.998 Q5ZLS8 →
Q96NH3 — 0.997 Q96NH3 →
Q3TCV3 — 0.997 Q3TCV3 →
Q3UPC7 — 0.997 Q3UPC7 →
Q8CE72 — 0.996 Q8CE72 →
Q6P2C0 — 0.996 Q6P2C0 →
O88196 — 0.996 O88196 →
Q9Y4E6 — 0.995 Q9Y4E6 →
Q6TNU3 — 0.995 Q6TNU3 →
SPG11 Spatacsin 0.995 landscape →
Q3MHH2 — 0.995 Q3MHH2 →
E1BGH8 — 0.995 E1BGH8 →
Q5H9S7 — 0.995 Q5H9S7 →
Q5ZKI7 — 0.994 Q5ZKI7 →
Q6INI0 — 0.994 Q6INI0 →
Q9DAU9 — 0.994 Q9DAU9 →
P53995 — 0.994 P53995 →
Q8NG48 — 0.994 Q8NG48 →
Q86VV8 — 0.994 Q86VV8 →
Q96N23 — 0.994 Q96N23 →
Q4R7B1 — 0.994 Q4R7B1 →
Q3UHQ6 — 0.994 Q3UHQ6 →
B1AUR6 — 0.994 B1AUR6 →
Q969F9 — 0.994 Q969F9 →
E1C2Z0 — 0.993 E1C2Z0 →
O60281 — 0.993 O60281 →
Q5SSH7 — 0.993 Q5SSH7 →